Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated CirrhosisPRNewsWire • 12/19/22
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022PRNewsWire • 11/09/22
Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused PipelinePRNewsWire • 11/03/22
Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS DisordersPRNewsWire • 09/26/22
Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)PRNewsWire • 09/15/22
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®PRNewsWire • 02/03/22
Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®PRNewsWire • 01/27/22
LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSISPRNewsWire • 12/22/21